Diabetes mellitus and cardiovascular risk. Recommendations of the working group of Diabetes Mellitus and Cardiovascular Disease of the Spanish Diabetes Society 2009{star, open};Diabetes mellitus y riesgo cardiovascular. Recomendaciones del grupo de trabajo Diabetes Mellitus y Enfermedad Cardiovascular de la Sociedad Española de Diabetes 2009

Clinica e Investigacion en Arteriosclerosis

Volumn 22, Issue 3, 2010, Pages 115-121

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MEDICAL SOCIETY; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; SMOKING; SPAIN;

EID: 77953363120     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/j.arteri.2010.03.004     Document Type: Article

References (38)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
2. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care 32 suppl 1 (2009) S13-S61
3. Barter P.J., Ballantyne C.M., Carmena R., Castro-Cabezas M., Chapman M.J., and Couture P. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Medicine 259 (2006) 247-258
4. Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 150 (2005) 859-870
5. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
6. Grover S.A., Coupal L., Zowall H., Alexander C.M., Weiss T.W., and Gomes D.R. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?. Diabetes Care 24 (2001) 45-50
7. Taylor D.C., Pandya A., Thompson D., Chu P., Graff J., Shepherd J., et al. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. Eur J Health Econ 10 (2009) 255-266
8. Varughese G.I., Tomson J., and Lip G.Y.H. Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract 59 (2005) 798-816
9. Peterson J.C., Adler S., Burkart J.M., Greene T., Hebert L.A., Hunsicker L.G., et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123 (1995) 754-762
10. Dahlöf B., Devereux R.D., Kjeldsen S.E., Julius S., Beevers G., de Faire U., and and LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
11. Lyons T.J., and Jemkins A.J. Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 8 (1997) 174-180
12. Selvin E., Coresh J., Golden S.H., Brancati F.L., Folsom A.R., and Steffes M.W. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165 (2005) 1910-1916
13. World Health Organization. WHO definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Definition, diagnosis and classification of diabetes. WHO Bull 1 (1999) 1-59
14. IDF. The IDF consensus worldwide definition of the metabolic syndrome 2005. www.idf.org.
15. Grundy S.M., Cleeman J.L., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute. Scientific Statement. Cardiol Rev 13 (2005) 322-327
16. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
17. Antiplatelet Trialists Collaboration: Collaborative overview of randomized trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
18. Dehghan A., Kardys I., de Maat M.P., Uitterlinden A.G., Sijbrands E.J., Bootsma A.H., et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56 (2007) 872-878
19. Dehghan A., van Hoek M., Sijbrands E.J.G., Stijnen T., Hofman A., and Witteman J.C.M. Risk of Type 2 Diabetes Attributable to C-Reactive Protein and Other Risk Factors. Diabetes Care 30 (2007) 2695-2699
20. Thorand B., Baumert J., Kolb H., Meisinger C., Chambless L., Koenig W., et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 30 (2007) 854-860
21. Pfohl M., and Schatz H. Strategies for the prevention of type 2 diabetes. Exp Clin Endocrinol Diabetes 109 Suppl. 2 (2001) S240-S242
22. Borghouts H., and Keizer A. Exercise and insulin sensitivity: A review. Int J Sports Med 21 (2000) 1-12
23. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
24. Diabetes Control Complications Trial Research Group (DCCT). The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent Diabetes Mellitus: the Diabetes Control and Complications Trial. N Eng J Med 329 (1993) 978-986
25. Holman R.R., Paul S.K., Bethel A.M., Matthews D.R., and Neil H.A. 10 years follow-up of intensive glucose control in type 2 Diabetes. N Eng J Med 359 (2008) 1577-1589
26. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al., Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycemia in type 2 diabetes: a consencus algorithm for the initiation and adjustement of therapy. Diabetologia 49 (2006) 1711-1721
27. Contois J.H., McConnell J.P., Sethi A.A., Csako G., Devaraj S., Hoefner D.M., et al. Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 55 (2009) 407-419
28. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-699
29. Sachdeva A., Cannon C.P., Deedwania P.C., LaBresh K.A., Smith S.C., Dai D., et al. Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J 157 (2009) 111-117
30. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol 95 (2005) 120-122
31. Franssen R., Vergeer M., Stroes E.S.G., and Kastelein J.J.P. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 11 (2009) 89-94
32. Hansson L., Zanchetti A., Carruthers S.G., Dahlöf B., Elmfeldt D., Julius S., et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
33. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 28 (2007) 1462-1536
34. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
35. Ridker P.M., Buring J.E., Shih J., Matias M., and Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98 (1998) 731-733
36. Godsland I.F., Elkeles R.S., Feher M.D., Nugara F., Rubens M.B., Richmond W., et al., PREDICT Study Group. Coronary calcification, homocysteine, C-reactive protein and the metabolic syndrome in Type 2 diabetes: the Prospective Evaluation of Diabetic Ischaemic Heart Disease by Coronary Tomography (PREDICT) Study. Diabet Med 23 (2006) 1192-1200
37. Friedman A.N., Hunsicker L.G., Selhub J., Bostom A.G., and Collaborative Study Group. C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int 68 (2005) 773-778
38. Mullenix P.S., Steele S.R., Martin M.J., Starnes B.W., and Andersen C.A. C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis. Arch Surg 142 (2007) 1066-1071